EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudie

Treatment‐Effect Heterogeneity and a Simple Framework for Estimating Survival Benefit Associated With Local Therapy in Nonmetastatic Advanced Prostate Cancer: A Multicenter KAMU ‐ ON Cohort Study

Hiroaki Iwamoto iD, Kouji Izumi iD, Kazuaki Machioka, Ren Toriumi, Takashi Shima, Masakazu Nozaki iD, Tomohiro Hori iD, Takahiro Inaba iD, Ryunosuke Nakagawa iD, Taiki Kamijima iD, Suguru Kadomoto iD, Tomoyuki Makino iD und 8 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70668 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Hiroaki Iwamoto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan. Hauptthemen laut MEDLINE: Prostatectomy, Prostatic Neoplasms. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate treatment‐effect heterogeneity associated with local therapy in nonmetastatic advanced prostate cancer and develop a simple hypothesis‐generating framework to estimate the expected absolute survival benefit associated with local therapy.

Methods

This multicentre retrospective cohort study included 1198 patients with clinical T3–4N0M0 or cN1M0 prostate cancer from the Kaga Million Uro‐Oncology Network (KAMU‐ON). Multivariable Cox models evaluated the association between local therapy and overall survival. Treatment‐effect heterogeneity was assessed using interaction analyses. Adjusted 5 year overall survival and absolute survival benefit were estimated by g ‐computation. A simple clinical framework based on clinicopathological variables was derived from the subgroup analyses.

Results

Local therapy was independently associated with improved overall survival (adjusted hazard ratio 0.32, 95% confidence interval 0.21–0.48; p < 0.001). Significant treatment‐effect heterogeneity was observed according to clinical T stage ( p for interaction = 0.030). The greatest absolute survival benefits were observed in patients with clinical T3b/T4 disease (20.3 percentage points) and Grade Group 4–5 disease (17.2 percentage points). The framework stratified the estimated absolute survival benefit from 0.1 to 19.5 percentage points across score groups ( p for interaction = 0.041; p for trend = 0.023).

Conclusions

The survival benefit associated with local therapy varied substantially across patients with nonmetastatic advanced prostate cancer. This hypothesis‐generating framework may provide estimates of expected treatment benefit and support individualized treatment discussions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstatectomyProstatic NeoplasmsAgedHumansMaleMiddle AgedJapanNeoplasm GradingNeoplasm StagingProportional Hazards ModelsProstateRetrospective StudiesSurvival RateTreatment Effect Heterogeneity

Stichwörter der Autor:innen

patient selectionprostatic neoplasmssurvival analysistreatment heterogeneitytreatment outcome

Autor:innen und Institutionen

  • Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan.
  • Department of Urology, Toyama Prefectural Central Hospital, Toyama, Toyama, Japan.
  • Department of Urology, Japanese Red Cross Fukui Hospital, Fukui, Fukui, Japan.

ORCID-Profile: Hiroaki Iwamoto, Kouji Izumi, Masakazu Nozaki, Tomohiro Hori, Takahiro Inaba, Ryunosuke Nakagawa, Taiki Kamijima, Suguru Kadomoto, Tomoyuki Makino, Renato Naito, Hiroshi Yaegashi, Kazuyoshi Shigehara, Takahiro Nohara, Yoshifumi Kadono, Atsushi Mizokami

Zitieren

APA

Iwamoto, H., Izumi, K., Machioka, K., Toriumi, R., Shima, T., Nozaki, M., Hori, T., Inaba, T., Nakagawa, R., Kamijima, T., Kadomoto, S., Makino, T., Naito, R., Yaegashi, H., Shigehara, K., Nohara, T., Miyagi, T., Seto, C., Kadono, Y., & Mizokami, A. (2026). Treatment‐Effect Heterogeneity and a Simple Framework for Estimating Survival Benefit Associated With Local Therapy in Nonmetastatic Advanced Prostate Cancer: A Multicenter KAMU ‐ ON Cohort Study. International Journal of Urology. https://doi.org/10.1111/iju.70668

Vancouver

Iwamoto H, Izumi K, Machioka K, Toriumi R, Shima T, Nozaki M, et al. Treatment‐Effect Heterogeneity and a Simple Framework for Estimating Survival Benefit Associated With Local Therapy in Nonmetastatic Advanced Prostate Cancer: A Multicenter KAMU ‐ ON Cohort Study. International Journal of Urology. 2026. doi:10.1111/iju.70668

BibTeX
@article{Iwamoto2026,
  author = {Iwamoto, Hiroaki and Izumi, Kouji and Machioka, Kazuaki and Toriumi, Ren and Shima, Takashi and Nozaki, Masakazu and Hori, Tomohiro and Inaba, Takahiro and Nakagawa, Ryunosuke and Kamijima, Taiki and Kadomoto, Suguru and Makino, Tomoyuki and Naito, Renato and Yaegashi, Hiroshi and Shigehara, Kazuyoshi and Nohara, Takahiro and Miyagi, Tohru and Seto, Chikashi and Kadono, Yoshifumi and Mizokami, Atsushi},
  title = {Treatment‐Effect Heterogeneity and a Simple Framework for Estimating Survival Benefit Associated With Local Therapy in Nonmetastatic Advanced Prostate Cancer: A Multicenter KAMU ‐ ON Cohort Study},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70668}
}
Kostenlos starten →